Use of Ziv Aflibercept in Different Retinal Diseases
- Sponsor
- Amin El Sayed Nawar
- Study ID
- NCT04290195
- Phase
- PHASE1/PHASE2
- Status
- Completed
Conditions
- Central Retinal Vein Occlusion With Macular Edema
Eligibility Criteria
- Sex
- ALL
- Age
- 31 Years - 63 Years
- Healthy Volunteers
- Accepted
Interventions
- Ziv-Aflibercept 25 MG/ML [Zaltrap] — DRUGIntravitreal injection of 1.25 mg of ziv aflibercept in patients
Study Details
A prospective interventional case series study was conducted on 20 eyes of 20 patients with active myopic choroidal neovascularisation (CNV) ,20 eyes with resistant diabetic macular edema and 15 eyes with non ischaemic central retinal vein occlusion(CRVO) after approval of the Ethical Committee of the Faculty of Medicine, Tanta University . All procedures were carried out under the tenets of the Helsinki Declaration. Written consent was provided by all participants after discussing the procedure, alternative treatment plans, follow-up schedules, and possible benefits and risks.
Key Dates
- Start date
- Jun 1, 2019
- Status verified
- Oct 2021
- Primary completion
- Dec 1, 2019
- Completion
- Jan 1, 2020
Study Design
- Enrollment
- 55 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: ziv aflibercept patients20 eyes of myopic CNV,20 eyes with resistant diabetic macular edema and 15 eyes with non ischaemic CRVO
Primary Outcome Measure
Improvement of BCVA by log MAR(minimum angle of resolution) and reduction of CMT after intravitreal injection [ Time Frame: 6 months ]